December 10–14, 2008 at the Henry B. Gonzalez Convention Center. Learn more about this event.
Meet nominated nurses who have demonstrated exceptional commitment to caring for their patients.
Meet some of the women who have battled HER2+ breast cancer in the Herceptin era. We hope that you will find inspiration in their strength and passion for life.
Download: BCIRG 006 Slide Kit (PPT, 7.7MB).
Review the proposed Herceptin Mechanism of Action.
BCIRG 006 included more than 3,200 patients and examined the safety and efficacy of two adjuvant Herceptin-containing regimens in patients with HER2+ breast cancer. 2 Patients were required to have either node-positive disease, or node-negative disease with at least one of the following high-risk features: ER/PR-negative, tumor size > 2 cm, age < 35 years, or histologic and/or nuclear grade 2/3. Patients were randomized (1:1:1) to receive one of the following adjuvant regimens: 2
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:
Herceptin can cause oligohydramnios and fetal harm when administered to a pregnant woman.
The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.
Please see the Herceptin full prescribing information including Boxed WARNINGS and additional important safety information.
